International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. (Q53158179)

11 May 2018

title

International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. (English)

1 reference

11 May 2018

0 references

2

1 reference

11 May 2018

author name string

Jeffrey S Wefel

series ordinal

1

1 reference

11 May 2018

Tim Ahles

series ordinal

3

1 reference

11 May 2018

Sanne B Schagen

series ordinal

4

1 reference

11 May 2018

publication date

25 February 2011

1 reference

11 May 2018

Lancet Oncology Commission

published in

1 reference

11 May 2018

volume

12

1 reference

11 May 2018

page(s)

703-708

1 reference

11 May 2018

issue

7

1 reference

11 May 2018

Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive function in breast cancer patients receiving adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cancer as a risk factor for long-term cognitive deficits and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive functioning in breast cancer survivors: a controlled comparison

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive impairment associated with adjuvant therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

A Prospective, Longitudinal Study of the Functional Status and Quality of Life of Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

The effects of adjuvant chemotherapy on cognition in women with breast cancer--preliminary results of an observational longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive impairments associated with breast cancer treatments: results from a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Prechemotherapy alterations in brain function in women with breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Regional brain activation during verbal declarative memory in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Neuropsychological sequelae of non-central nervous system cancer and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Neurocognitive changes in cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive dysfunction in people with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

SSRIs and cognitive performance in a working sample.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Paced auditory serial-addition task: a measure of recovery from concussion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Practice effects during repeated administrations of memory tests with and without alternate forms.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Clinical significance: A statistical approach to defining meaningful change in psychotherapy research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Detecting significant change in neuropsychological test performance: a comparison of four models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Individual variation for cognitive decline: quantitative methods for describing patterns of change

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970294-1

7 January 2021

10.1016/S1470-2045(10)70294-1

Identifiers

DOI

1 reference

11 May 2018

PubMed ID

21354373

1 reference

11 May 2018